Ebola outbreak is DRC’s worst; where is the vaccine?

What the report says

The Independent Uganda reports that the Democratic Republic of the Congo is facing its largest recorded Ebola outbreak in the country, driven by the Bundibugyo strain, for which no approved vaccine exists. The article says the outbreak has spread across six provinces, with the main concentration in Ituri and continued transmission in North Kivu and Haut-Uélé. It also notes that WHO has described the situation as moving with unusual speed and not yet under control.

According to the report, CEPI has stepped up funding for vaccine development, including up to US$8.5 million for Hilleman Laboratories to advance a Bundibugyo vaccine candidate and prepare doses for human testing. The candidate is based on the same rVSV platform used in MSD’s Ervebo vaccine, but existing licensed Ebola shots target the Zaire species rather than Bundibugyo. The article adds that other Bundibugyo candidates, including one from Moderna and another from Oxford and the Serum Institute of India, are already in early human trials.

The piece places the outbreak in wider context by noting heavy illness and death among children and health workers, and by saying early cases may have been misidentified as malaria or typhoid. It also highlights the practical challenge of vaccine deployment in eastern DRC, where cold-chain and infrastructure limits complicate response efforts.

More broadly, the article frames the episode as part of a recurring global pattern in which outbreak preparedness lags behind emergencies, while CEPI continues to seek major new funding for its “100 Days Mission” to speed future vaccine development.